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Summary 
Heat shock protein 90 (HSP90) is a molecular chaperone that regulates critical signalling 
proteins of cancer development and progression. Abnormal levels of HSP90 have been 
observed in human prostatic carcinoma (PC), with prognostic and therapeutic implications. 
Since spontaneously arising canine PC is a valuable model for the human disease, the aim of 
this study was to evaluate the immunohistochemical expression of HSP90 in two normal 
canine prostates, 17 canine prostates with benign prostatic hyperplasia (BPH) and five canine 
prostates with PC.  HSP90 was expressed in the cytoplasm of epithelial cells in all samples; 
with a significant increase in labelled cells in PCs. Nuclear labelling was observed 
occasionally in normal tissue, but was increased in BPH and PC.  HSP90 immunoreactivity in 
preneoplastic lesions (proliferative inflammatory atrophy and prostatic intraepithelial 
neoplasia) was similar to that in PCs.  Increased HSP90 expression in canine PCs suggests the 
involvement of this molecule in carcinogenesis and tumour progression, supporting HSP90 as 
a potential target for therapeutic intervention.  
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Prostatic carcinoma (PC) is a significant cause of morbidity and mortality in the western 
world (Jemal et al., 2010) and, despite an excellent initial response to the androgen 
deprivation therapy, the failure rate is high with the emergence of the aggressive castration-
resistant PC (CRPC).  Controlling CRPC presents a challenge that requires new treatment 
strategies.  In addition to man, the dog is the only mammal that spontaneously develops 
invasive PC (Waters and Bostwick, 1997), with a disease process similar to that of man 
(Rosol et al., 2003).  PC in dogs is typically late stage and androgen independent, therefore 
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representing a useful model to explore the mechanisms of cancer progression in both species 
(Leroy and Northrup, 2009). 
Heat shock proteins (HSPs) are highly conserved molecular chaperones involved in a 
diverse range of normal intracellular activities and in different pathogenic processes 
(Morimoto et al., 1990).  Up-regulation of HSPs is observed commonly in cancer cells and is 
believed to support malignant transformation (Sreedhar et al., 2004).  HSP90 is the most 
abundant HSP within cells and is therefore considered an anti-cancer target (Scaltriti et al., 
2012).  Inhibition of HSP90 is of particular significance for PC since HSP90 is overexpressed 
in prostate cancer cells with a stage- and malignancy-dependent expression (Cornford et al., 
2000; Cardillo and Ippoliti, 2006).  In-vitro, the androgen receptor (AR)-negative prostate 
cancer cell line PC-3, corresponding to a more advanced stage of PC development, has higher 
HSP90 expression than the LNCaP cell line, which is androgen-sensitive and AR-positive and 
represents an early stage of PC (Stope et al., 2012).   The AR is one of the HSP90 ‘client 
proteins’ as it binds HSP90 as part of a multimolecular complex.  The AR drives the growth 
of CRPC through a number of mechanisms that intimately rely on HSP90 for cell survival, 
especially AR overexpression and gain-of-function AR gene mutations (Waltering et al., 
2012).   Many preclinical studies have shown the potential utility of HSP90 inhibitors in 
prostate cancer (Eskew et al., 2011; O’Malley et al., 2012) and new-generation HSP90 
inhibitors with improved physical and pharmacological properties may achieve more durable 
suppression of CRPC growth and minimize drug resistance (Centenera et al., 2013).  
Importantly, some HSP90 inhibitors (e.g. Ganetespib®; Synta Pharmaceuticals Corporation, 
Lexington, Massachusetts, USA) appear to be effective in cells expressing splice variants of 
the AR that are devoid of the ligand binding domain and therefore resistant to conventional 
AR antagonists (He et al., 2013).  HSP90 inhibitors have been used in a phase I study of a 
canine model of spontaneously arising cancer (London et al., 2011) and HSP90 expression 
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has been shown in a few primary tumours of the dog, including mammary cancer (Romanucci 
et al., 2006) and osteosarcoma (Romanucci et al., 2012), with an expression pattern 
paralleling the human counterparts. All of these findings strongly support the potential use of 
the canine model for testing new HSP90-targeted cancer therapy and studying human 
carcinogenesis.  The aim of the present study was to evaluate immunohistochemically the 
expression of HSP90 in normal, hyperplastic, preneoplastic and carcinomatous canine 
prostatic epithelial cells.     
Formalin-fixed, paraffin wax-embedded samples of canine prostate were selected from 
the departmental archive, unfortunately without follow-up data. Tissue samples included two 
normal prostates (dogs aged 5 and 6 years), 17 cases of benign prostatic hyperplasia (BPH) 
and five PCs.  BPH and PC samples were from dogs aged 5–11 years (mean 7 years) and 8–
11 years (mean 9 years), respectively.  Sections (5 µm) were stained with haematoxylin and 
eosin (HE).  PCs were classified according to Lai et al. (2008).  
Immunohistochemistry (IHC) was performed using an avidin–biotin–peroxidase 
system (Vectastain Standard Elite; Vector Laboratories, Burlingame, California, USA) as 
described by Romanucci et al. (2012).  A murine monoclonal anti-human HSP90 
(StressGen/Assay Designs, Inc., Ann Arbor, Michigan, USA; 1 in 1,800 dilution) was used as 
primary antibody. The primary antibody was omitted from negative control sections, which 
were incubated with phosphate buffered saline.   Sections of normal canine testes were used 
as positive controls.  
The intensity (i.e. weak, moderate or strong) and distribution (i.e. nuclear, perinuclear 
or diffuse cytoplasmic) of antigen labelling in normal, hyperplastic and neoplastic cells was 
recorded.  The percentage of labelled cells was calculated semiquantitatively in 10 high-
power fields (×400) as follows: (1) percentage of positively labelled cells/total cells (positive 
score), (2) percentage of cells with nuclear labelling/total positive cells (nuclear-positive 
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score), (3) percentage of cells with perinuclear labelling/total positive cells (perinuclear-
positive score), and (4) percentage of cells with diffuse cytoplasmic labelling/total positive 
cells (diffuse cytoplasmic-positive score).  Both assessments were made independently by two 
pathologists.  HSP90 expression was classified as: grade I, no labelled cells; grade II, up to 
10% of cells labelled; grade III, 10–50% of cells labelled; grade IV, >50% of cells labelled. 
Results were expressed as percentage of cases of each grade out of the total number of cases 
in each category (i.e. normal, BPH and PC).  To compare the IHC scores, differences in 
percentages were calculated with the Chi-square test.  P <0.01 was considered significant.  
Epithelial hyperplasia, mild stromal fibrosis and cystic acini were observed in 
hyperplastic lesions.  PCs had different histological patterns: (1) small acinar/ductal (n = 2), 
(2) cribriform with multifocal central necrosis (n = 2), or (3) undifferentiated (n = 1).  In two 
of the five cases of PC, neoplastic emboli were detected within blood vessels.  Metastases to 
the lung and lymph nodes were observed in one case of PC.  Preneoplastic lesions, such as 
proliferative inflammatory atrophy (PIA) and prostatic intraepithelial neoplasia (PIN) were 
observed in five samples.   Multifocal areas of PIA (Supplementary Fig. 1) were observed in 
four cases of BPH and one case of undifferentiated adenocarcinoma; multifocal epithelial 
PIN-like proliferations were observed admixed with PIA lesions in one case of BPH.  
Moderate to strong HSP90 expression was demonstrated in samples of BPH and PC, 
and in PIN and PIA lesions, while mild to moderate labelling was present in normal prostatic 
cells.  Significantly fewer labelled cells were present in normal prostate (20–30% of cells 
were positive, grade III) (Fig. 1) than in BPH (Fig. 2) and PC. In all PCs and most cases of 
BPH (82.3%), the labelled cells comprised >50% of the entire cell population (grade IV), 
while 17.7% of samples of BPH contained 10–50% labelled cells (Table 1).  The cytoplasmic 
distribution of HSP90 was predominantly perinuclear in normal cells, both perinuclear and 
diffuse in BPH, and mainly diffuse in PC, PIN and PIA.  Nuclear labelling was observed 
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occasionally in normal tissue, with progressively more nuclear expression in BPH and PC 
(Fig. 3).  A significant difference in nuclear score was observed between normal prostate and 
BPH (grade II, III, IV; P <0.01), normal prostate and PC (grade II, III, IV; P <0.01) and BPH 
and PC (grade II; P <0.01).  The metastases observed in one case of PC had labelling that was 
similar in distribution and score to that of the primary tumour (Supplementary Fig. 2).  In PIA 
and PIN lesions, a high number of cells had nuclear labelling (Supplementary Fig. 3).  The 
mean scores are summarized in Table 1.   
The results of the present study have therefore demonstrated increased 
immunohistochemical labelling for HSP90 in canine PC cells compared with normal and 
hyperplastic prostates, suggesting a role for this protein in prostatic carcinogenesis and 
neoplastic progression, as in man (Bubendorf et al., 1999; Cornford et al., 2000; Akalin et al., 
2001; Zellweger et al., 2005; Kurahashi et al., 2007).  High HSP90 expression has been 
reported in advanced human PC with high Gleason grade (Isaacs et al., 2003; Lebret et al., 
2003; Solit et al., 2003; Cardillo and Ippoliti, 2006); however, in the present cases HSP90 
expression was not associated with any specific histological type of PC and the lack of 
follow-up information has hindered any correlation with biological behaviour and prognosis.  
HSP90 is involved in regulation of the cell cycle (Helmbrecht et al., 2000) and it can 
initiate cellular proliferation by affecting proteins necessary for cell growth (Pechan, 1991).  
This would account for the increased expression of the molecule in canine prostatic 
hyperplasia, as occurs in human prostate (Thomas et al., 1996; Akalin et al., 2001).  Studies 
of mammary gland (Zagouri et al., 2010) and endometrium (Wataba et al., 2001) support the 
involvement of this protein in the pathogenesis of benign proliferative lesions, as HSP90 
expression follows the continuum of epithelial cell transformation from precursors through 
pre-invasive to carcinomatous lesions in the mammary gland and from the proliferative phase 
of the menstrual cycle in the endometrium to pathological endometrial hyperplasia.  
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The high expression of this chaperone protein in PIA and PIN is similar to that 
observed in PC, suggesting that increased HSP90 expression is a relatively early event during 
prostatic carcinogenesis.  Zellweger et al. (2005) and Elmore et al. (2008) have shown that 
HSP90 is differentially expressed in PIN compared with BPH and therefore HSP90 
immunolabelling could minimize the likelihood that a small focus of intraepithelial neoplasia 
is overlooked in a microscopical field of hyperplastic tissue. The characterization of 
preneoplastic lesions in the dog is still under investigation, as demonstrated by the sparse 
literature on PIA (Rodrigues et al., 2010; Toledo et al., 2010) and PIN (Aquilina et al., 1998; 
Leroy and Northrup, 2009). However, the occurrence of PIA and PIN in normal and 
hyperplastic tissues should be carefully considered when examining canine prostate excisional 
biopsies, even if the tissue is normal or the lesion benign. 
In the present study, the neoplastic epithelial cells and cells in PIA and PIN lesions 
were characterized by increased nuclear immunoreactivity compared with normal and 
hyperplastic prostate.  Approximately 3% of the intracellular HSP90 pool is found in the 
nucleus (Csermely et al., 1998) and this chaperone protein can regulate several nuclear 
events, contributing to tumourigenesis (Trepel et al., 2010).  Among these, HSP90 regulates 
the activity of the heat shock transcription factor (HSF)-1 involved in cell survival under 
stressful conditions (Trepel et al., 2010).  In the nucleus, HSP90 is known to bind to BCL-6 
with this complex suppressing the transcription of several tumour suppressor genes 
(Cerchietti et al., 2009), and to regulate telomerase assembly and function (Holt et al., 1999). 
Akalin et al. (2001) observed specific nuclear expression of HSP90 in human PC cells, 
suggesting that the protein remains associated with the functional telomerase enzyme 
(Forsythe et al., 2001).  Gebhard et al. (1999) found a positive correlation between HSP90 
nuclear labelling and high expression of class I molecules of the major histocompatibility 
complex (MHC) in human breast cancer, with lack of HSP90 nuclear localization in tumours 
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with reduced MHC class I expression.  Tumour cells with high MHC class I expression and 
susceptibility to cytotoxic T lymphocytes may escape apoptosis by a mechanism involving 
increased expression of nuclear HSP90 (Gebhard et al., 1999).  However, the most important 
nuclear event for prostate carcinogenesis regulated by HSP90 is the activity of steroid 
hormone receptors (SHRs), including AR.  HSP90 is crucial for modulating SHR cellular 
location, protein stability, ability to bind ligand and transcriptional activity (Echeverria et al., 
2009).  Androgens drive prostate tumour growth; hence many therapies aim to reduce the 
synthesis of circulating androgens and/or inhibit the AR itself (Jenster, 1999). In androgen-
refractory prostate cancer, AR remains active despite androgen ablative conditions (Zegarra-
Moro et al., 2002).  The mechanism of the apparent loss of hormone dependence is poorly 
understood; several models have been proposed, including changes in the intracellular 
trafficking of AR leading to ligand-independent nuclear importation or impairment of nuclear 
export (Feldman and Feldman, 2001). The ligand-dependent nuclear translocation of AR can 
be inhibited by the HSP90 inhibitor geldanamycin, suggesting a role for HSP90 in the nuclear 
importation of AR (Georget et al., 2002).  Saporita et al. (2007) have demonstrated that a 
geldanamycin derivative, 17-AAG, can prevent the ligand-independent nuclear localization of 
AR in C4-2 cells, a model for androgen-refractory prostate cancer cells, partially restoring 
androgen-dependent regulation of AR and thus potentially providing an improved efficacy of 
androgen ablation therapy.  
In conclusion, we have demonstrated that HSP90 is consistently up-regulated in 
malignant canine prostatic epithelial cells, strongly supporting the canine model for further 
testing of HSP90-targeted cancer therapy.  We believe that increased expression of this 
chaperone protein may have prognostic value in predicting prostate cancer or 
tumorigenic/metastatic potential in less aggressive disease.  Further studies into tumour grade 
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and biological behaviour will be critical to understanding the role of this chaperone protein 
during prostate cancer progression.  
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Figure Legends 
Fig. 1.  Multifocal perinuclear HSP90 expression in normal canine prostate. IHC. ×600. 
  
Fig. 2.  Benign prostatic hyperplasia showing diffuse HSP90 expression.  IHC. ×100. 
  
Fig. 3.  Strong and diffuse nuclear and cytoplasmic HSP90 labelling of prostate cancer cells. 
IHC. ×600. 
  
 
Supplementary Figure Legends 
Fig. 1.  Preneoplastic lesions (proliferative inflammatory atrophy) randomly scattered in the 
canine prostate (arrows).  Note the inflammatory cells infiltrating the surrounding tissue. HE. 
×100. 
 
Fig. 2.  Prostate cancer metastatic to the lung with a high number of HSP90-positive cells. 
IHC. ×100. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
Fig. 3.  PIA foci showing epithelial cells with strong nuclear and cytoplasmic HSP90 
expression. IHC. ×600. 
 
 
Legend to Graphical Abstract 
HSP90 expression increases as epithelium transforms from preinvasive to carcinomatous 
lesions in the canine prostate. 
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Table 1 
HSP90 expression in normal, hyperplastic and neoplastic canine prostate 
 
 Positive score  
(% of positive 
cells/total cells) 
Nuclear-positive score 
 (% of cells with 
nuclear labelling/total 
positive cells) 
Perinuclear-
positive 
score 
 (% cases) 
Diffuse 
cytoplasmic-
positive 
score 
 (% cases) 
Grade I II III IV I II III IV   
Normal 
prostate* 
0 0 100 0 0 100 0 0 100 0 
BPH* 0 0 17.7 82.3 5.9 23.5 35.3 35.3 23.5 76.5 
PC* 0 0 0 100 0 0 40 60 0 100 
 
Grade: I, no labelling; II, up to 10% of cells labelled; III, 10–50% of cells labelled; IV, >50% 
of cells labelled. 
*Percentage of cases/total cases 
BPH, benign prostatic hyperplasia; PC, prostatic carcinoma 
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